48
Participants
Start Date
July 22, 2020
Primary Completion Date
November 7, 2022
Study Completion Date
January 31, 2025
GNR-051
Anti-PD1 monoclonal antibody
"FSBI N.N. Blokhin National Medical Research Center of Oncologyof the Ministry of Health of the Russian Federation", Moscow
"FSBI Russian Scientific Center of Roentgenoradiology of the Ministry of Health of the Russian Federation", Moscow
"FSAEI HE I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russian Federation", Moscow
"JSC MEDSI Group of Companies", Moscow
"FSII Treatment and Rehabilitation Center of the Ministry of Health of the Russian Federation", Moscow
"SBHI Leningrad Regional Clinical Oncology Dispensary", Saint Petersburg
"JSC Modern Medical Technologies", Saint Petersburg
"FSAEI HE I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation", Saint Petersburg
"FSBI N.N. Petrov National Medical Research Center of Oncology of the Ministry of Healthcare of the Russian Federation", Moscow
"SBHI St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)", Saint Petersburg
"LLC Tentanda Via", Saint Petersburg
"SAHI Republican Clinical Oncological Dispensary of the Ministry of Health of the Republic of Tatarstan", Kazan'
AO GENERIUM
INDUSTRY